Table 2.
Top canonical pathways associated with TrkB deletion in mouse striatal MSNs
| Canonical pathway: | -log (p-value): | Ratio: | Molecules: |
|---|---|---|---|
| Thrombin signaling |
2.69E + 00 |
5.34E-02 |
ARHGEF10, MPRIP, GATA1, RHOT2, ADCY1, GNB5, CAMK1G, HRAS, PRKCH, GNG7, PRKCB |
| Protein kinase A signaling |
2.63E + 00 |
4.28E-02 |
SHH, PTPN7, PTPRE, SMAD3, DUSP6, GNB5, PTPN5, TCF7, GNG7, PTEN, ADD3, ADCY1, SMAD4, RYR1, PRKCH, CDC16, PRKCB |
| Galpha(i) signaling |
2.44E + 00 |
6.06E-02 |
GRM8, NPY1R, ADCY1, GNB5, HRAS, ADRA2C, STAT3, GNG7 |
| Prolactin signaling |
2.39E + 00 |
7.50E-02 |
HRAS, PRKCH, STAT3, SOCS5, TCF7, PRKCB |
| CXCR4 signaling |
2.36E + 00 |
5.36E-02 |
EGR1, RHOT2, ADCY1, GNB5, HRAS, PRKCH, ELMO1, GNG7, PRKCB |
| Glutamate receptor signaling |
2.18E + 00 |
7.25E-02 |
GRM8, SLC1A1, HOMER1, GNG7, GRIK1 |
| Galpha(s) signaling |
2.11E + 00 |
5.79E-02 |
RGS2, ADD3, ADCY1, GNB5, RYR1, HTR6, GNG7 |
| Cell cycle: G1/S checkpoint regulation |
2.06E + 00 |
7.58E-02 |
PA2G4, HDAC8, SMAD3, SMAD4, CDKN1B |
| Beta-adrenergic signaling |
2.04E + 00 |
5.71E-02 |
ADCY1, GNB5, HRAS, PRKCH, GNG7, PRKCB |
| Phospholipase C signaling |
2.04E + 00 |
4.23E-02 |
ARHGEF10, MPRIP, HDAC8, RHOT2, ADCY1, GNB5, ITGA5, HRAS, PRKCH, GNG7, PRKCB |
| Neuregulin signaling |
2.00E + 00 |
5.88E-02 |
ITGA5, HRAS, PRKCH, CDKN1B, PTEN, PRKCB |
| G Beta gamma signaling |
2.00E + 00 |
5.13E-02 |
ADCY1, GNB5, HRAS, PRKCH, GNG7, PRKCB |
| RAR activation |
1.98E + 00 |
4.76E-02 |
SMAD3, ADCY1, SMAD4, PRKCH, ERCC2, PTEN, PPARGC1A, RBP4, PRKCB |
| Virus entry via endocytic pathways |
1.97E + 00 |
6.06E-02 |
ITGA5, TFRC, HRAS, PRKCH, CXADR, PRKCB |
| Chronic myeloid leukemia signaling |
1.86E + 00 |
5.71E-02 |
PA2G4, HDAC8, SMAD3, SMAD4, HRAS, CDKN1B |
| Glioma signaling |
1.84E + 00 |
5.36E-02 |
PA2G4, CAMK1G, HRAS, PRKCH, PTEN, PRKCB |
| Axonal guidance signaling |
1.77E + 00 |
3.42E-02 |
SHH, GNB5, HRAS, SEMA6B, ITGA5, FZD1, SLIT2, GIT1, GNG7, NTNG1, SEMA3A, SUFU, BAIAP2, ABLIM2, PRKCH, PRKCB |
| Breast cancer regulation by stathmin1 |
1.73E + 00 |
4.35E-02 |
ARHGEF10, ADCY1, GNB5, CAMK1G, HRAS, PRKCH, CDKN1B, GNG7, PRKCB |
| Molecular mechanisms of cancer |
1.60E + 00 |
3.44E-02 |
SHH, PA2G4, SMAD3, RHOT2, HRAS, FZD1, ARHGEF10, SUFU, ADCY1, SMAD4, PRKCH, CDKN1B, PRKCB |
| Renin-angiotensin signaling |
1.60E + 00 |
4.80E-02 |
ADCY1, HRAS, SHC3, PRKCH, STAT3, PRKCB |
| CREB signaling in neurons |
1.56E + 00 |
3.94E-02 |
GRM8, ADCY1, GNB5, HRAS, PRKCH, GNG7, GRIK1, PRKCB |
| Androgen signaling |
1.55E + 00 |
4.17E-02 |
SMAD3, GNB5, PRKCH, ERCC2, GNG7, PRKCB |
| ErbB2-ErbB3 signaling |
1.51E + 00 |
6.67E-02 |
HRAS, STAT3, CDKN1B, PTEN |
| Calcium signaling |
1.48E + 00 |
3.79E-02 |
TNNT1, HDAC8, CAMK1G, TPM2, RYR1, TRPC4, CASQ2, GRIK1 |
| 14-3-3-mediated signaling |
1.45E + 00 |
4.96E-02 |
STK11, TSC2, HRAS, PRKCH, CDKN1B, PRKCB |
| P2Y purigenic receptor signaling pathway |
1.42E + 00 |
4.35E-02 |
ADCY1, GNB5, HRAS, PRKCH, GNG7, PRKCB |
| PTEN signaling |
1.42E + 00 |
4.44E-02 |
INPP5F, FLT1, ITGA5, HRAS, CDKN1B, PTEN |
| IL-8 signaling |
1.41E + 00 |
3.90E-02 |
FLT1, RHOT2, GNB5, HRAS, PRKCH, IRAK3, GNG7, PRKCB |
| cAMP-mediated signaling | 1.41E + 00 | 4.02E-02 | RGS2, GRM8, NPY1R, DUSP6, ADCY1, CAMK1G, ADRA2C, HTR6, STAT3 |
Microarray data were analyzed through the use of IPA (Ingenuity® Systems, http://www.ingenuity.com).
The p-value was calculated using the right-tailed Fisher Exact Test, considering the number of molecules participating in a given pathway and the total number of molecules associated with that pathway in Ingenuity’s knowledge base.